Clinical outcome and safety of rituximab therapy for pemphigoid diseases - 14/04/20
![](/templates/common/images/mail.png)
Funding sources: Supported by the Faculty of Medicine, Chiang Mai University, Thailand. |
|
Conflicts of interest: Dr Payne is a co-founder and equity holder in Cabaletta Bio, Inc, focused on targeted immunotherapy of pemphigus. She is an inventor on patents licensed by Novartis and Cabaletta Bio for cellular immunotherapy of autoimmune diseases and has previously served as a consultant for Syntimmune, Inc. These organizations had no involvement in the research reported in this study. Dr Tovanabutra has no conflicts of interest to declare. |
|
Reprints not available from the authors. |
Vol 82 - N° 5
P. 1237-1239 - mai 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?